The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase III cardiovascular outcomes trial, analysts had hoped for statistical ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

Shares of Eli Lilly and Company (NYSE:LLY) dropped Thursday morning after the company announced that its diabetes treatment ...

Several new weight loss drugs are undergoing trials in the UK. These drugs will work similarly to those already available but ...

WEIGHT loss jabs could raise the risk of sudden blindness, a study warns. Injections like Wegovy, Mounjaro and Ozempic are ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Moderna announced layoffs affecting 10% of its workforce amid government and competitive challenges to its vaccine business ...

As discussed in this LipoVive review, the formula is a natural weight loss aid made with clinically approved herbs and plant ...

Jessica Philips, 30, had been overweight for her entire life - but a trip to Italy last year was a turning point.